Privi Speciality Chemicals Ltd — earnings calls

Privi Speciality Chemicals reported Q1 FY27 revenue of Rs. 666 crore, up 19.22% year-on-year, with EBITDA of Rs. 167.47 crores and EBITDA margin of 24.58%. Management attributed growth to a mix of volume, price increases and improved product mix, while gross margin compressed due to a normalization from the prior year's low-cost raw material advantage. The company also filed its scheme with the NCLT for the proposed merger of Privi Speciality Chemicals, Privi Fine Sciences and Privi Biotechnologies, and discussed progress on Phase-1 and Phase-2 capacity expansions.

Privi Speciality Chemicals reported FY26 revenue growth of about 22% and EBITDA growth of 40.35%, with EBITDA margin expanding to 25.76% from 22.35% a year earlier. Management attributed the growth to a mix of volume growth, price increases and product mix improvement, and said the PRIGIV joint venture with Givaudan turned profitable in the fourth quarter. The company also outlined capacity expansion plans, including a first capex phase due for completion by June 2026 and new speciality molecules such as ethyl maltol, maltol and cyclopentanone targeted for mechanical completion around mid-2026.